12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sapacitabine: Additional Phase II data

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J.
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Product: Sapacitabine ( CYC682)
Business: Cancer
Molecular target: DNA polymerase
Description: Cell cycle modulating nucleoside analog
Indication: Treat myelodysplastic syndromes (MDS)
Endpoint: One-year survival; overall response rate (ORR), hematological improvement, transfusion requirements, hospitalization days and overall survival (OS)
Status: Additional Phase II...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >